Literature DB >> 19330474

IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not.

Kerstin Wolk1, Harald S Haugen, Wenfeng Xu, Ellen Witte, Kim Waggie, Monica Anderson, Elmar Vom Baur, Katrin Witte, Katarzyna Warszawska, Sandra Philipp, Caroline Johnson-Leger, Hans-Dieter Volk, Wolfram Sterry, Robert Sabat.   

Abstract

Psoriasis is a common chronic skin disease with a largely unknown pathogenesis. We demonstrate here that transgenic over-expression of interleukin (IL)-22 in mice resulted in neonatal mortality and psoriasis-like skin alterations including acanthosis and hypogranularity. This cutaneous phenotype may be caused by the direct influence of IL-22 on keratinocytes, since this cytokine did not affect skin fibroblasts, endothelial cells, melanocytes, or adipocytes. The comparison of cytokines with hypothesized roles in psoriasis pathogenesis determined that neither interferon (IFN)-gamma nor IL-17, but only IL-22 and, with lower potency, IL-20 caused psoriasis-like morphological changes in a three-dimensional human epidermis model. These changes were associated with inhibited keratinocyte terminal differentiation and with STAT3 upregulation. The IL-22 effect on differentiation-regulating genes was STAT3-dependent. In contrast to IL-22 and IL-20, IFN-gamma and IL-17 strongly induced T-cell and neutrophilic granulocyte-attracting chemokines, respectively. Tumor necrosis factor-alpha potently induced diverse chemokines and additionally enhanced the expression of IL-22 receptor pathway elements and amplified some IL-22 effects. This study suggests that different cytokines are players in the psoriasis pathogenesis although only the IL-10 family members IL-22 and IL-20 directly cause the characteristic epidermal alterations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330474     DOI: 10.1007/s00109-009-0457-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  44 in total

1.  Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes.

Authors:  S V Kotenko; L S Izotova; O V Mirochnitchenko; E Esterova; H Dickensheets; R P Donnelly; S Pestka
Journal:  J Biol Chem       Date:  2000-10-16       Impact factor: 5.157

2.  Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo.

Authors:  Marie Le Borgne; Nathalie Etchart; Anne Goubier; Sergio A Lira; Jean Claude Sirard; Nico van Rooijen; Christophe Caux; Smina Aït-Yahia; Alain Vicari; Dominique Kaiserlian; Bertrand Dubois
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

3.  Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model.

Authors:  Shigetoshi Sano; Keith Syson Chan; Steve Carbajal; John Clifford; Mary Peavey; Kaoru Kiguchi; Satoshi Itami; Brian J Nickoloff; John DiGiovanni
Journal:  Nat Med       Date:  2004-12-12       Impact factor: 53.440

4.  Interleukin 20: discovery, receptor identification, and role in epidermal function.

Authors:  H Blumberg; D Conklin; W F Xu; A Grossmann; T Brender; S Carollo; M Eagan; D Foster; B A Haldeman; A Hammond; H Haugen; L Jelinek; J D Kelly; K Madden; M F Maurer; J Parrish-Novak; D Prunkard; S Sexson; C Sprecher; K Waggie; J West; T E Whitmore; L Yao; M K Kuechle; B A Dale; Y A Chandrasekher
Journal:  Cell       Date:  2001-01-12       Impact factor: 41.582

5.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

6.  Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types.

Authors:  L Dumoutier; C Leemans; D Lejeune; S V Kotenko; J C Renauld
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

Review 7.  Infliximab for the treatment of psoriasis.

Authors:  C Elise Kleyn; Christopher E M Griffiths
Journal:  Expert Opin Biol Ther       Date:  2006-08       Impact factor: 4.388

Review 8.  The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder.

Authors:  Sandra Philipp; Kerstin Wolk; Stephanie Kreutzer; Elizabeth Wallace; Nina Ludwig; Joachim Roewert; Conny Höflich; Hans-Dieter Volk; Wolfram Sterry; Robert Sabat
Journal:  Expert Opin Ther Targets       Date:  2006-12       Impact factor: 6.902

9.  Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells.

Authors:  Eva V Acosta-Rodriguez; Laura Rivino; Jens Geginat; David Jarrossay; Marco Gattorno; Antonio Lanzavecchia; Federica Sallusto; Giorgio Napolitani
Journal:  Nat Immunol       Date:  2007-05-07       Impact factor: 25.606

10.  Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol.

Authors:  John Rømer; Erik Hasselager; Peder Lisby Nørby; Torben Steiniche; Jes Thorn Clausen; Knud Kragballe
Journal:  J Invest Dermatol       Date:  2003-12       Impact factor: 8.551

View more
  144 in total

Review 1.  Structure and function of interleukin-22 and other members of the interleukin-10 family.

Authors:  Daniela Barretto Barbosa Trivella; José Ribamar Ferreira-Júnior; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

2.  IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.

Authors:  Emily Y Jen; Nancy J Poindexter; Elizabeth S Farnsworth; Elizabeth A Grimm
Journal:  Melanoma Res       Date:  2012-02       Impact factor: 3.599

3.  Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.

Authors:  Melissa G Works; Fangfang Yin; Catherine C Yin; Ying Yiu; Kenneth Shew; Thanh-Thuy Tran; Nahoko Dunlap; Jennifer Lam; Tim Mitchell; John Reader; Paul L Stein; Annalisa D'Andrea
Journal:  J Immunol       Date:  2014-08-25       Impact factor: 5.422

4.  Development of a bioengineered skin-humanized mouse model for psoriasis: dissecting epidermal-lymphocyte interacting pathways.

Authors:  Sara Guerrero-Aspizua; Marta García; Rodolfo Murillas; Luisa Retamosa; Nuria Illera; Blanca Duarte; Almudena Holguín; Susana Puig; Maria Isabel Hernández; Alvaro Meana; Jose Luis Jorcano; Fernando Larcher; Marta Carretero; Marcela Del Río
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

5.  Withasteroid B from D. metel L. regulates immune responses by modulating the JAK/STAT pathway and the IL-17+ RORγt+ /IL-10+ FoxP3+ ratio.

Authors:  Y Su; Q Wang; B Yang; L Wu; G Cheng; H Kuang
Journal:  Clin Exp Immunol       Date:  2017-08-04       Impact factor: 4.330

Review 6.  Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases.

Authors:  Mitchell E Menezes; Praveen Bhoopathi; Anjan K Pradhan; Luni Emdad; Swadesh K Das; Chunqing Guo; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

7.  IL-22 secreted by decidual stromal cells and NK cells promotes the survival of human trophoblasts.

Authors:  Ying Wang; Bing Xu; Ming-Qing Li; Da-Jin Li; Li-Ping Jin
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

8.  IL-22 is essential for lung epithelial repair following influenza infection.

Authors:  Derek A Pociask; Erich V Scheller; Sivanarayana Mandalapu; Kevin J McHugh; Richard I Enelow; Cheryl L Fattman; Jay K Kolls; John F Alcorn
Journal:  Am J Pathol       Date:  2013-03-11       Impact factor: 4.307

Review 9.  IL-22 in tissue-protective therapy.

Authors:  Heiko Mühl; Patrick Scheiermann; Malte Bachmann; Lorena Härdle; Anika Heinrichs; Josef Pfeilschifter
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 10.  Emerging role of interleukin-22 in autoimmune diseases.

Authors:  Hai-Feng Pan; Xiang-Pei Li; Song Guo Zheng; Dong-Qing Ye
Journal:  Cytokine Growth Factor Rev       Date:  2012-08-18       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.